<DOC>
	<DOCNO>NCT02792517</DOCNO>
	<brief_summary>A pharmacokinetic drug interaction study AMG 334 oral contraceptive contain progestin estrogen .</brief_summary>
	<brief_title>AMG 334 Plus Combined Oral Contraceptive Drug Interaction Study Healthy Females</brief_title>
	<detailed_description>A pharmacokinetic drug interaction study AMG 334 oral contraceptive contain progestin estrogen . Approximately 35 subject enrol . All subject receive oral contraceptive contain progestin estrogen throughout duration study . Subjects also receive single dose AMG 334 , administer healthcare provider . Serial PK sample collect specified time point characterize PK oral contraceptive contain progestin estrogen without presence AMG 334 .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Healthy female ≥18 ≤45 year old time enrollment Regular monthly menstrual cycle last 12 month Good general health base medical history evaluation physical examination No clinically significant abnormality laboratory test screen Subject provide informed consent/assent prior initiation study specific activities/procedures Intolerance recent oral contraceptive last three ( 3 ) year , Female subject positive serum pregnancy test screen Female subject willing inform sexual partner participation clinical study Use counter prescription medication within 14 day 5 half life ( whichever longer ) Nicotine use eg cigarette equivalent 12 month prior day 1 duration study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>